Recommendations for Subsequent Zika IgM Antibody Testing

Summary

Testing for Zika virus infection using real-time reverse-transcription polymerase chain reaction (rRT-PCR) molecular assays is now commercially available. When requesting Zika rRT-PCR testing from a commercial laboratory, providers should be aware that commercial laboratories performing rRT-PCR currently do not also offer Zika IgM enzyme-linked immunosorbent assay (ELISA) or confirmatory serologic testing (plaque reduction neutralization test, or PRNT). Therefore, if possible, providers should store a serum aliquot for subsequent Zika IgM ELISA testing if the commercial rRT-PCR assay is negative. Otherwise, collection of an additional serum sample may be necessary. Both rRT-PCR testing for Zika virus and Zika IgM antibody testing is available through the Oklahoma State Department of Health (OSDH) Public Health Laboratory (PHL). Health care providers should contact the OSDH Acute Disease Service Epidemiologist-On-Call at (405) 271-4060 for questions or clarification regarding this guidance or access Zika virus testing through the OSDH PHL.

Recommendations

- rRT-PCR (molecular) testing should be performed for patients possibly exposed to Zika virus who have symptoms consistent with Zika virus infection.
- Appropriate samples for molecular testing are serum samples collected <7 days and urine samples collected <14 days after symptom onset. Urine should always be collected with a patient-matched serum specimen.
- Providers who request molecular testing for Zika virus infection from a commercial testing laboratory are advised to retain and store in a refrigerator (2-8°C) an aliquot of the patient’s serum for subsequent Zika IgM ELISA testing if the rRT-PCR is negative.
- For specimens that are rRT-PCR negative from the commercial laboratory and no stored serum specimen is available, another serum specimen should be collected within 12 weeks of symptom onset for Zika IgM ELISA testing.

Background

Molecular assays for detection of Zika virus RNA are now commercially available under Emergency Use Authorizations (EUAs) issued by the Food and Drug Administration (FDA). CDC recommends molecular testing using rRT-PCR for serum samples collected <7 days and urine samples collected <14 days after symptom onset. A positive rRT-PCR test is confirmation of Zika virus infection. However, because of the decline in the level of viremia over time and possible inaccuracy in reporting of dates of illness onset, a negative rRT-PCR result does not exclude Zika virus infection. In such cases, CDC recommends serologic testing by ELISA for Zika IgM antibody.

Currently, commercial laboratories that offer rRT-PCR testing do not provide Zika IgM ELISA testing with PRNT confirmation and have no routine process to forward specimens to another testing laboratory. Therefore, when requesting Zika rRT-PCR testing from a commercial laboratory, providers should retain an aliquot of the serum for Zika IgM ELISA testing if the rRT-PCR testing is negative. Blood should be collected and processed per routine guidelines (collected in a serum separator tube with serum aliquots transferred to new vials), and one of the serum aliquots should be stored in a refrigerator (2-8°C) until it is known if additional IgM testing is indicated. If a serum aliquot cannot be stored or is not available, but further testing is indicated, a new blood sample should be collected. Serum samples for IgM testing should be collected from patients within 12 weeks of symptom onset. Oklahoma healthcare providers should contact the OSDH Acute Disease Service (ADS) Epidemiologist-on-Call at (405) 271-4060 to discuss IgM testing of stored or newly collected serum from patients who are rRT-PCR negative.
For More Information

- Interim guidance for Zika virus testing of urine: [http://www.cdc.gov/mmwr/volumes/65/wr/mm6518e1.htm](http://www.cdc.gov/mmwr/volumes/65/wr/mm6518e1.htm)

Health care providers should contact the ADS Epidemiologist-On-Call at (405) 271-4060 for questions or clarification regarding this guidance or Zika virus testing.

---

### Agency: Oklahoma State Department of Health

<table>
<thead>
<tr>
<th>Notification ID: 239</th>
<th>Date: 06/23/2016</th>
<th>Time: 4:00 pm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severity: Moderate</td>
<td>Acknowledgement: No</td>
<td>Sensitive: No</td>
</tr>
<tr>
<td>Notification Type: Update</td>
<td>Reference: OKHAN 234, 236, 237 &amp; 238</td>
<td>Dissemination: As Needed &amp; CDCHAN-00392</td>
</tr>
</tbody>
</table>

---

Categories of Health Alert messages

- **Health Alert**  highest level of notification that the Oklahoma State Department of Health will send out. This usually refers to an immediate threat to the OSDH community and requires immediate action.
- **Health Advisory** advises medical providers of a condition in the area. These are usually not medical emergencies. These may not require immediate action.
- **Health Update**  provides updates on previous alerts or advisories. These are unlikely to require immediate action.

## This advisory has been distributed to Primary Care and Obstetrics & Gynecology Physicians, Emergency Departments, Infection Preventionists, Advance Practice Nurses, Laboratorians and State and Local Health Officials ##

You have received this message based upon the information contained within our emergency notification database. If you have a different or additional e-mail or fax address that you would like us to use please contact the OSDH Acute Disease Service at (405) 271-4060.

*****************************************************************************************